Clinical Trials

Endometrial Serous Adenocarcinoma

NCT04633239 2026-03-18

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

42 enrolled

Recurrent Ovarian High Grade Serous Adenocarcinoma

NCT04704661 2026-03-18

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

BreastGastrointestinalGynecologicHead & NeckSarcoma

51 enrolled

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04840589 2026-03-18

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Phase 1 Suspended

66 enrolled

Neoplasm Metastasis, Ovarian Neoplasms

NCT05554328 2026-03-18

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

165 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05554367 2026-03-18

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

GastrointestinalGynecologic

199 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms

NCT05564377 2026-03-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

2,900 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05691504 2026-03-18

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

42 enrolled

GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Endometrial Neoplasms

NCT05950464 2026-03-18

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

60 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Endometrial Neoplasms

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Phase 1/2 Completed

224 enrolled 15 charts

Phase 1/2 Active not recruiting

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

NCT01116648 2026-03-05

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

155 enrolled 34 charts

BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT02345265 2026-03-05

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

70 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06935344 2026-03-03

PROVE

Recruiting

1,300 enrolled

Genetic Risk Score, Ovarian Neoplasms

NCT07211204 2026-03-03

Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population

Phase NA Withdrawn

Phase 1/2 Active not recruiting

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Atypical Squamous Cells of the Cervix

NCT04432597 2026-02-17

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

39 enrolled

GastrointestinalGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Rectal Neoplasms

NCT05465941 2026-02-09

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

43 enrolled

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03120624 2026-02-04

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

34 enrolled 16 charts

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT04095364 2026-01-14

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

450 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07327489 2026-01-08

ELEPHAS-05

Recruiting

2,000 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

GastrointestinalGenitourinaryGynecologic

30 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1 Withdrawn

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05276973 2025-12-19

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Phase 1 Active not recruiting

25 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06639074 2025-10-02

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

78 enrolled

GynecologicSarcoma

Advanced Fallopian Tube Carcinoma

NCT05998135 2025-09-11

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

28 enrolled

Ovarian High Grade Serous Adenocarcinoma

NCT03367741 2025-07-28

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

82 enrolled

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT05920798 2025-06-22

FRAPPE

Phase 1/2 Recruiting

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05672095 2025-05-23

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

Phase 1/2 Withdrawn

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04616534 2025-05-22

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

14 enrolled

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT04919629 2025-05-11

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

60 enrolled

Phase EARLY_PHASE1 Terminated

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00436254 2025-04-06

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

Phase 1 Completed

66 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT04906382 2025-02-13

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

2 enrolled

GastrointestinalGynecologic

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms

NCT06289062 2024-11-05

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

40 enrolled

Uterine Cervical Neoplasms

NCT05673252 2024-04-17

CERTIFIKO

Recruiting

128 enrolled

Phase NA Not yet recruiting

Uterine Cervical Neoplasms

NCT06366516 2024-04-16

MTTRIHPW

10,000 enrolled

Phase EARLY_PHASE1 Withdrawn

Squamous Intraepithelial Lesions, Adenocarcinoma in Situ

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05048173 2023-09-15

Sentinel Lymph Node Biopsy Versus Lymphadenectomy in Endometrial Cancer

Completed

334 enrolled

Early Stage Endometrial Cancer

NCT00503581 2020-11-03

Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia

Phase 2 Terminated

9 enrolled 5 charts

Squamous Intraepithelial Lesions

NCT04072913 2019-08-28

MMP-HPV

216 enrolled

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT03846856 2019-04-04

The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical Significance

Unknown

40 enrolled

Ovarian Neoplasms

NCT00504023 2018-06-06

Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva

8 enrolled 7 charts

BreastGenitourinaryGynecologicHead & NeckSarcoma

Vulvar Neoplasms

NCT00004261 2018-02-22

EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma

Phase 1 Terminated

Breast Carcinoma In Situ, Breast Neoplasms, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Inflammatory Breast Neoplasms

NCT03020121 2018-01-31

Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples

Phase NA Terminated

28 enrolled

GynecologicOther neoplasm

Uterine Cervical Neoplasms

NCT00629577 2017-02-01

SAGE

Phase 1 Terminated

50 enrolled

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Precancerous Conditions

NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Phase 2 Completed

59 enrolled 6 charts

EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

NCT00900302 2016-02-10

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

Completed

98 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Melanoma, Neoplasms, Neoplasms, Unknown Primary, Penile Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Vulvar Neoplasms, Breast Neoplasms, Male

NCT00550589 2015-12-21

Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus

Phase 2 Completed

33 enrolled 11 charts

GastrointestinalGynecologicOther neoplasm

Squamous Intraepithelial Lesions, Anus Neoplasms, Precancerous Conditions

NCT00003429 2015-12-18

PET Scans in Diagnosing Primary or Recurrent Cervical Cancer in Patients Who Are Undergoing Surgery

Uterine Cervical Neoplasms

NCT00049231 2013-06-24

EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer